News from biotrends research group A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jun 20, 2013, 09:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

Use of Erythropoiesis Stimulating Agents Has Declined Over the Past Year in the U.S. Dialysis Setting, While Oral Iron Use in Dialysis Has Increased

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that the use...

Jun 11, 2013, 10:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

Despite the Numerous Agents in Development for the Treatment of Chronic HCV Infections, a Notable Share of Physicians in Europe Lack Awareness of the HCV Pipeline

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds in their...

Jun 05, 2013, 09:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

Phosphate Binder Use Has Declined Over the Past Two Years in the U.S. Dialysis Setting, While Sensipar Use in Hemodialysis has Declined Since Last Year

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that the use...

May 30, 2013, 10:24 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

For Multiple Sclerosis Treatment, Prescriber Base for Genzyme's Aubagio Among U.S. Neurologists Has Increased Significantly at Six Months Post-launch, Compared to One and Three Months Post-launch

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that over half of...

May 29, 2013, 09:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

Despite Lucentis's Recent Expanded Label for Diabetic Macular Edema, Avastin Remains the Preferred Intravitreal Therapy for Diabetic Macular Edema in the United States

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that,...

May 29, 2013, 09:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

Rheumatoid Arthritis Patients are Moderately to Highly Satisfied with Their Current Drug Therapy, Rating Conventional DMARDs Highest on Ease of Use and Cost

BioTrends Research Group, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that rheumatoid...

May 23, 2013, 10:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, unaided,...

May 06, 2013, 09:33 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

Surveyed Physicians Indicate that Xtandi is Prescribed to Nearly One Quarter of Metastatic Castrate-Resistant Prostate Cancer Patients Who Have Failed to Respond to Prior Docetaxel Treatment

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, at six...

May 02, 2013, 09:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that...

Apr 25, 2013, 09:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

Long-Term Safety, Reduction in Disease Activity/Flares and Sustained Efficacy are Among the Key Unmet Needs for New Systemic Lupus Erythematosus (SLE) Treatments

 BioTrends Research Group, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the top...

Apr 24, 2013, 09:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

At Three Months Post Launch, Two-Thirds of Surveyed U.S. Rheumatologists Believe that Initiations of Pfizer's Xeljanz in the Rheumatoid Arthritis Treatment Algorithm Will Occur Following at Least Two Biologic Failures

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that two-thirds...

Apr 15, 2013, 12:00 ET

The Significant Number Of Countries With Biosimilar Regulatory Pathways And A Global Desire For More Affordable Healthcare Support The Introduction Of A Global Regulatory Process For Biosimilars

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that the...

Apr 15, 2013, 09:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

Hemodialysis Patient Share for Sanofi's Ferrlecit Increased Significantly in the First Quarter of 2013 Compared to the Previous Quarter

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that in...

Apr 08, 2013, 10:00 ET

Both Biosimilar and Reference Biologics Companies Must consider Various Product-Specific and Regional Strategies to Navigate a Dynamic and Uncertain Global Market

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, with sales...

Apr 08, 2013, 09:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

Lack of Familiarity and Hospital Formulary Inclusion Pose Key Barriers to Dificlir Uptake in European Markets for the Treatment of CDAD

 BioTrends Research Group and Arlington Medical Resources in their TreatmentTrends®: Clostridium difficile Infections (EU) report find...

Apr 04, 2013, 10:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

ESAs and a New Class of Late Stage Oral HIF-PH Inhibitors May Be Impacted by the Fact That Nephrologists Report Initiating ESAs at Lower Hemoglobins

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, compared to...

Apr 02, 2013, 08:00 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

Incorporation of the Anti-JC Virus Antibody Assay and Oral DMAs, Including Aubagio, are Top of Mind Recent Changes in the Management of Multiple Sclerosis Patients for Surveyed U.S. Neurologists

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that...

Apr 01, 2013, 08:15 ET

Two New Strategic Reports Expand Coverage Of BioTrend's Biosimilars Advisory Service

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, has released two...

Mar 25, 2013, 11:00 ET
Mar 25, 2013, 10:51 ET
BioTrends Research Group Logo.  (PRNewsFoto/BioTrends Research Group)

Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists

 BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceuticals issues, finds that,...